Vivek Subbiah, MD, associate professor in the department of investigational cancer therapeutics, MD Anderson, is the world-renowned guest on the show this week to tackle the world of precision medicine in cancer. He begins by explaining how precision medicine is more than simply a “fancier” mechanism of treatment than chemotherapy, why tumor sequencing is important even though there aren’t drugs available for every possible mutation, how much the field has advanced even in the past 10 years, the intricacies of designing clinical trials, and lots more.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
